Tim G Eisen
Overview
Explore the profile of Tim G Eisen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wason J, Mander A, Eisen T
Eur J Cancer
. 2011 Jan;
47(7):983-9.
PMID: 21239164
Reducing the number of patients required for a clinical trial is important for shortening development time. Phase II cancer trials assess the tumour-shrinking effect of a novel compound through a...
2.
Forman J, Worth C, Bickerton G, Eisen T, Blundell T
Proteins
. 2009 May;
77(1):84-96.
PMID: 19408298
Mutations in the VHL gene lead to von Hippel-Lindau (VHL) disease, a clinically heterogeneous cancer syndrome. Here, we use software and database tools to understand and predict the phenotypes associated...
3.
Yap T, Eisen T
Clin Genitourin Cancer
. 2006 Oct;
5(2):120-30.
PMID: 17026800
Metastatic renal cell carcinoma (RCC) has a highly variable natural history and carries a dismal prognosis. Unlike many other tumors, RCC is generally unresponsive to cytotoxic, hormonal, and radiation adjuvant...
4.
Lynch T, Adjei A, Bunn Jr P, Eisen T, Engelman J, Goss G, et al.
Clin Cancer Res
. 2006 Jul;
12(14 Pt 2):4365s-4371s.
PMID: 16857812
No abstract available.
5.
Larkin J, Norsworthy P, AHern R, Eisen T, Gore M, Porter C
Melanoma Res
. 2006 Mar;
16(2):157-63.
PMID: 16567971
Antibodies to the cell surface disaccharide galactose(alpha1,3)galactose (alphaGal) are the most prevalent natural antibodies in human serum. The anti-alphaGal immunoglobulin M-dependent activation of complement causes hyperacute rejection of organ transplants...
6.
Shah R, Ahmad T, Eisen T
Expert Rev Anticancer Ther
. 2004 Dec;
4(6):1069-80.
PMID: 15606334
The management of recurrent renal cell carcinoma is challenging as it requires close collaboration between surgeons, radiation oncologists and medical oncologists. To date, treatment options for metastatic disease have been...
7.
Atkins M, Avigan D, Bukowski R, Childs R, Dutcher J, Eisen T, et al.
Clin Cancer Res
. 2004 Sep;
10(18 Pt 2):6277S-81S.
PMID: 15448017
No abstract available.
8.
Lens M, Eisen T
Expert Opin Pharmacother
. 2003 Dec;
4(12):2205-11.
PMID: 14640919
Different postsurgical therapies are used for the treatment of metastatic melanoma. This article reviews the use of chemotherapeutic agents in the treatment of patients with metastatic malignant melanoma. A variety...
9.
Smalley K, Eisen T
Int J Cancer
. 2003 Apr;
105(2):165-75.
PMID: 12673674
The constitutive activity of a number of growth and cell survival pathways are thought to contribute to the inherent resistance of melanoma to chemotherapy and radiotherapy. Many of these pathways...
10.
Smalley K, Eisen T
Int J Cancer
. 2002 Mar;
98(4):514-22.
PMID: 11920610
Novel classes of drug that interfere with the signalling of the small G-protein Ras, the so-called Ras antagonists, are showing much promise as novel anti-cancer agents. In this study, we...